← Back to patent-cliff list
VK-2019
Tier C — Watch / tradeVK-2019
Cullinan Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EBNA-1
Indications (approved)：鼻咽肿瘤, EB病毒感染, Diffuse large B-cell lymphoma, Nasopharyngeal carcinoma
Regional status
US
Phase II
2019-04-04
EU
Discontinued
2019-04-04
China
Phase I
2019-12-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of VK-2019?
Approved indications include: 鼻咽肿瘤, EB病毒感染, Diffuse large B-cell lymphoma, Nasopharyngeal carcinoma.
When does the VK-2019 patent expire?
No public expiry year is available for VK-2019 yet; this page updates once verified.
How do I get a quote for VK-2019 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08